Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149514 (bronchitis)
 6,902 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Relatively few studies have addressed the issue of the Minnesota Multiphasic Personality Inventory (MMPI) alexithymia scale's construct validity. In this study, the validity of the scale is supported by the finding of a significantly lower percentage of alexithymic individuals in a large sample of psychiatric inpatients than in samples of patients with a variety of physical disorders (i.e., migraine headaches, asthma bronchitis/emphysema, and hypertension). Validity of the scale is further supported through a comparison of the alexithymic and nonalexithymic psychiatric inpatients on a series of Rorschach and MMPI variables. As predicted, alexithymics were less verbally productive, displayed less ability to fantasize, and demonstrated greater defensive pseudonormality. Results suggest the measure may be of value in studies of psychiatric patients as well as those with physical disorders.
 ...
PMID:The construct validity of the MMPI alexithymia scale with psychiatric inpatients. 321 Jan 18

A cross-sectional epidemiological investigation of the health status of 261 people from 85 private households previously treated with chlordane for termite control was conducted to assess potential human health effects. When sinusitis, bronchitis, and migraine responses were compared to measured indoor air levels of chlordane in categories designated as low (less than 1 microgram/m3), medium (1-5 micrograms/m3), and high (greater than 5 micrograms/m3), a dose-response relationship was found after controlling individually and simultaneously for age, sex, and smoking. Homes studied in this investigation having a proper chlordane application were observed to have chlordane air levels exceeding acceptable exposure limits.
 ...
PMID:A preliminary study of potential human health effects in private residences following chlordane applications for termite control. 326 84

The authors report the onset of wheezing and dyspnea in a 32-year-old, nonasthmatic male who was receiving propranolol for chronic migraine headaches of 20 years' duration. The symptoms first appeared during the "cold season"; the diagnosis was bronchitis. After three months without propranolol, the patient, prompted by continuing migraine headaches, again took the drug (40 mg bid). Within 48 hours he complained of rhinitis that rapidly progressed to wheezing, resembling bronchitis. Other reports in the literature are discussed.
 ...
PMID:Propranolol-induced dyspnea in a nonasthmatic male. 714 May 15

This article reviews recent studies conducted in Europe which sought to evaluate the effectiveness of Peter Mandel's Esogetic Colorpuncture Therapy (ECT). These investigations addressed the use of specific ECT therapies for treating a variety of difficult health problems: migraines, childhood insomnia, bronchitis, ADD or learning disorders, and uterine fibroids. Limitations in research design and sample size necessitate that these studies be viewed as pilot or preliminary research. However, in all the studies, the findings showed dramatic improvement of symptoms after ECT treatments. This suggests that ECT may offer fast, economical, non-invasive and non-toxic methods for treating the selected health problems and that ECT continues to show promise as a powerful new method of wholistic healing.
 ...
PMID:A review of recent research studies on the efficacy of Esogetic Colorpuncture Therapy--A wholistic acu-light system. 1051 1

Many chronic illnesses that affect the working population can cause losses in productivity. The extent to which these productivity losses can be reduced by pharmacological treatment is of particular interest to employers, who bear the productivity costs and subsidize the cost of employees' health care. In the past several years, the effects of pharmaceuticals on productivity losses have been tested in numerous studies, including randomized, double-blind, placebo-controlled trials. In this article, we summarize and critically review these studies and, where appropriate, provide quantitative overviews. The evidence is very good for about a dozen drug classes that pharmaceuticals reduce productivity losses caused by respiratory illnesses (ie, asthma, allergic disorders, bronchitis, upper respiratory infections, and influenza) diabetes, depression, dysmenorrhea, and migraine. We also discuss the calculation of productivity costs, reductions in which may partially or completely offset the costs of treatment. This information should be helpful to occupational physicians who are increasingly providing recommendations on employer benefit plan designs and pharmaceutical benefits.
 ...
PMID:Pharmaceuticals and worker productivity loss: a critical review of the literature. 1280 14

Migraine is one of the common diseases, suffering 8.4 million patients in Japan. Recently conditions associated with chronic migraine were considered to be worse than episodic migraine in socio-economic status, health-related quality of life, and headache-related burden. Preventing the chronification, and improving treatment and management, the natural disease course could give us some clues. Several reports suggested that a population prevalence of chronic migraine is about 2% and approximately 2.5% of patients with episodic migraine develop new-onset chronic migraine each year. The risk factors for converting episodic to chronic migraine were demonstrated as follows: age, low education/socioeconomic status, head injury, attack frequency, obesity, medication overuse, stressful life events, caffeine overuse, snoring, other pain syndromes, allodynia, proinflammatory states, prothrombotic states, and specific genes. It was also focused in comobidity with chronic migraine, such as depression, anxiety, chronic pain, asthma, bronchitis, hypertension, and so on. The ratio converting in reverse was reported as a fourth in two years. We should recognize the burden of migraine patients, and improve patients' outcome under reducing risk factors and assessing the effect of treatment on headache progression.
 ...
PMID:[Clinical course and natural history in migraine]. 2227 14

Primula veris L. is an important medicinal plant with documented use for the treatment of gout, headache and migraine reaching back to the Middle Ages. Triterpenoid saponins from roots and flowers are used in up-to-date phytotherapeutic treatment of bronchitis and colds due to their expectorant and secretolytic effects. In addition to the wild type plants with yellow petals, a red variant and an intermediate orange form of Primula veris L. have recently been found in a natural habitat. The secondary metabolite profiles of roots, leaves and flowers of these rare variants were investigated and compared with the wild type metabolome. Two flavonoids, six flavonoid glycosides, four novel methylated flavonoid glycosides, five anthocyanins and three triterpenoid saponins were identified in alcoholic extracts from the petals, leaves and roots of the three variants by high performance liquid chromatography (HPLC)-diode array detection (DAD)/mass spectrometry (MSn) analyses. Anthocyanins were detected in the petals of the red and orange variety, but not in the wild type. No other effects on the metabolite profiles of the three varieties have been observed. The possibility is discussed that a regulatory step of the anthocyanin biosynthetic pathway may have been affected by mutation thus triggering color polymorphism in the petals.
 ...
PMID:Comparative Metabolite Profiling of Triterpenoid Saponins and Flavonoids in Flower Color Mutations of Primula veris L. 2809 96